<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473655</url>
  </required_header>
  <id_info>
    <org_study_id>DM-CRESTOR-0002</org_study_id>
    <nct_id>NCT00473655</nct_id>
  </id_info>
  <brief_title>Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients</brief_title>
  <official_title>A Double-blind, Double Dummy, Phase IV, Randomized, Multicenter, Parallel Group, Placebo Controlled Trial to Evaluate the Effect of Rosuvastatin on Triglycerides Levels in Mexican Hypertriglyceridemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and
      20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride
      levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction from baseline to end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-HDL-C Reduction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C Reduction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol Reduction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C Increase</measure>
    <time_frame>8 weeks</time_frame>
    <description>Increase from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoA1 Levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in the levels from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP Reduction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Reported</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of participants with AEs and SAEs reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB Levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in the levels from baseline to end of study</description>
  </secondary_outcome>
  <enrollment type="Actual">334</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Hyperlipoproteinemia Type IV</condition>
  <condition>Hyperlipoproteinemia Type V</condition>
  <condition>Hyperlipoproteinemia Type IIb</condition>
  <condition>Hyperlipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>10mg or 20mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years, both genders, without any previous treatment with
             statins or other lipid lowering drugs for at least 6 months

          -  With elevated triglycerides above 200 and below 800mg/dl and willing to follow all
             study procedures including assisting to clinics, fasting before blood samples and
             signing a written consent

        Exclusion Criteria:

          -  High levels of low-density lipoprotein cholesterol (LDL-C)

          -  Unstable cardiovascular condition or awaiting a myocardial revascularization

          -  Congestive cardiac failure

          -  Uncontrolled diabetes

          -  Cancer

          -  Uncontrolled hypothyroidism

          -  Familial hypercholesterolemia

          -  Liver/muscle disease

          -  Pregnancy

          -  Other
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Polanco, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Polanco, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Talavera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMSS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <results_first_submitted>May 10, 2010</results_first_submitted>
  <results_first_submitted_qc>May 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2010</results_first_posted>
  <last_update_submitted>November 30, 2010</last_update_submitted>
  <last_update_submitted_qc>November 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <keyword>Triglycerides</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>statins</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>hyperlipoproteinemia</keyword>
  <keyword>Fredrickson Type IIb or IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type IV</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants where outpatients recruited from clinical centers. Recruitment began on August 2007 and ends on October 2008</recruitment_details>
      <pre_assignment_details>Participants with informed consent signed, and all inclusion criteria with no exclusion criteria, entered the lead in period, where they received a low fat diet. After 4 weeks if they still had TGs above 200 mg/dl they entered the randomization phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin 10 mg</title>
          <description>Rosuvastatin 10 mg</description>
        </group>
        <group group_id="P2">
          <title>Rosuvastatin 20 mg</title>
          <description>Rosuvastatin 20 mg</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111">Just participants with TG above 200 mg/dl entered this period</participants>
                <participants group_id="P2" count="112">Just participants with TG above 200 mg/dl entered this period</participants>
                <participants group_id="P3" count="111">Just participants with TG above 200 mg/dl entered this period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102">9 participants were lost of follow up</participants>
                <participants group_id="P2" count="107">5 participants were lost of follow up</participants>
                <participants group_id="P3" count="103">8 participants were lost of follow up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin 10 mg</title>
          <description>Rosuvastatin 10 mg</description>
        </group>
        <group group_id="B2">
          <title>Rosuvastatin 20 mg</title>
          <description>Rosuvastatin 20 mg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="111"/>
            <count group_id="B4" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.57" spread="12.77"/>
                    <measurement group_id="B2" value="53.14" spread="12"/>
                    <measurement group_id="B3" value="51.48" spread="13.47"/>
                    <measurement group_id="B4" value="52.4" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arterial Hypertension</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Arterial Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes mellitus</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index continuous</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Body mass index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.72" spread="5.11"/>
                    <measurement group_id="B2" value="29.77" spread="4.04"/>
                    <measurement group_id="B3" value="30.36" spread="4.90"/>
                    <measurement group_id="B4" value="30.28" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-C levels, continuous</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.50" spread="7.52"/>
                    <measurement group_id="B2" value="34.05" spread="6.88"/>
                    <measurement group_id="B3" value="32.30" spread="6.49"/>
                    <measurement group_id="B4" value="33.28" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C, continuous</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129.24" spread="28.23"/>
                    <measurement group_id="B2" value="130.51" spread="29.19"/>
                    <measurement group_id="B3" value="129.77" spread="31.10"/>
                    <measurement group_id="B4" value="129.84" spread="29.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TG levels, continuous</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Tg levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="319.51" spread="131.95"/>
                    <measurement group_id="B2" value="296.78" spread="95.19"/>
                    <measurement group_id="B3" value="309.46" spread="99.55"/>
                    <measurement group_id="B4" value="308.25" spread="110.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)</title>
        <description>Reduction from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)</title>
          <description>Reduction from baseline to end of study</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.95" spread="128.46"/>
                    <measurement group_id="O2" value="78.61" spread="121.51"/>
                    <measurement group_id="O3" value="22.31" spread="120.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-HDL-C Reduction</title>
        <description>Reduction from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL-C Reduction</title>
          <description>Reduction from baseline to end of study</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.76" spread="48.08"/>
                    <measurement group_id="O2" value="61.31" spread="46.63"/>
                    <measurement group_id="O3" value="1.06" spread="37.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-C Reduction</title>
        <description>Reduction from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-C Reduction</title>
          <description>Reduction from baseline to end of study</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.23" spread="28.58"/>
                    <measurement group_id="O2" value="53.22" spread="32.80"/>
                    <measurement group_id="O3" value="-2.66" spread="28.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol Reduction</title>
        <description>Reduction from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Reduction</title>
          <description>Reduction from baseline to end of study</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.73" spread="41.13"/>
                    <measurement group_id="O2" value="63.32" spread="42.97"/>
                    <measurement group_id="O3" value="-1.44" spread="34.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL-C Increase</title>
        <description>Increase from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HDL-C Increase</title>
          <description>Increase from baseline to end of study</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" spread="7.16"/>
                    <measurement group_id="O2" value="2.49" spread="5.78"/>
                    <measurement group_id="O3" value="1.95" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ApoA1 Levels</title>
        <description>Change in the levels from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>ApoA1 Levels</title>
          <description>Change in the levels from baseline to end of study</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="23.38"/>
                    <measurement group_id="O2" value="6.79" spread="18.60"/>
                    <measurement group_id="O3" value="2.65" spread="19.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hsCRP Reduction</title>
        <description>Reduction from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>hsCRP Reduction</title>
          <description>Reduction from baseline to end of study</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="1.16"/>
                    <measurement group_id="O2" value="0.11" spread="0.35"/>
                    <measurement group_id="O3" value="-0.01" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Reported</title>
        <description>Number of participants with AEs and SAEs reported</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Reported</title>
          <description>Number of participants with AEs and SAEs reported</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ApoB Levels</title>
        <description>Change in the levels from baseline to end of study</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 10 mg</title>
            <description>Rosuvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>ApoB Levels</title>
          <description>Change in the levels from baseline to end of study</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.05" spread="26.92"/>
                    <measurement group_id="O2" value="-36.81" spread="23.51"/>
                    <measurement group_id="O3" value="1.43" spread="26.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin 10 mg</title>
          <description>Rosuvastatin 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Rosuvastatin 20 mg</title>
          <description>Rosuvastatin 20 mg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Femur And Rotula Right Fracture That Required Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cephalea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Leg Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI has the right to publish Study results in scientific journals. PI may use the Study results but not publish any results until: the date of the first Study results publication or the end of the 18-month period following the completion of the Study. PI shall provide AZ with the material for review. AZ has the right to publish the Study results</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>09645895 ext 44 15</phone>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

